Skip to main content
OpenTrials

Clinical trial condition

Castration-Resistant Prostate Carcinoma

Explore clinical trials studying Castration-Resistant Prostate Carcinoma. Study availability and eligibility vary by location and protocol.

54 public trials 15 recruiting studies
Refine in advanced search Browse all conditions

Castration-Resistant Prostate Carcinoma trial results

Completed

Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

NCT01576172

Conditions
Castration-Resistant Prostate Carcinoma, Genital Diseases, Genital Diseases, Male, +10 more
Locations
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • USC / Norris Comprehensive Cancer Center Los Angeles, California, United States
  • City of Hope South Pasadena South Pasadena, California, United States
  • University of Chicago Comprehensive Cancer Center Chicago, Illinois, United States
View all 14 locations
View Trial Details
Completed

Molecular Features and Pathways in Predicting Drug Resistance in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Enzalutamide

NCT02228265

Conditions
Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Genital Diseases, +13 more
Locations
  • UCLA / Jonsson Comprehensive Cancer Center Los Angeles, California, United States
  • UCSF Medical Center-Mount Zion San Francisco, California, United States
  • OHSU Knight Cancer Institute Portland, Oregon, United States
View Trial Details
Completed

CYT107 After Vaccine Treatment (Provenge®) in Patients With Metastatic Castration-Resistant Prostate Cancer

NCT01881867

Conditions
Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Genital Diseases, +11 more
Locations
  • UC San Diego Moores Cancer Center La Jolla, California, United States
  • USC / Norris Comprehensive Cancer Center Los Angeles, California, United States
  • UCSF Medical Center-Mount Zion San Francisco, California, United States
  • UCSF Medical Center-Mission Bay San Francisco, California, United States
View all 16 locations
View Trial Details
Active, Not Recruiting

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

NCT04550494

Conditions
Adnexal Diseases, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, +64 more
Locations
  • UF Health Cancer Institute - Gainesville Gainesville, Florida, United States
  • National Cancer Institute Developmental Therapeutics Clinic Bethesda, Maryland, United States
  • National Institutes of Health Clinical Center Bethesda, Maryland, United States
  • University of Oklahoma Health Sciences Center Oklahoma City, Oklahoma, United States
View Trial Details
Active, Not Recruiting

Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel

NCT03419234

Conditions
Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Genital Diseases, +12 more
Locations
  • Fairbanks Memorial Hospital Fairbanks, Alaska, United States
  • CTCA at Western Regional Medical Center Goodyear, Arizona, United States
  • Kingman Regional Medical Center Kingman, Arizona, United States
  • Mercy Hospital Fort Smith Fort Smith, Arkansas, United States
View all 672 locations
View Trial Details
Active, Not Recruiting

Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer

NCT02893917

Conditions
Advanced Prostate Adenocarcinoma With Neuroendocrine Differentiation, Castration-Resistant Prostate Carcinoma, Genital Diseases, +13 more
Locations
  • UC San Diego Moores Cancer Center La Jolla, California, United States
  • University of California Davis Comprehensive Cancer Center Sacramento, California, United States
  • UC San Diego Medical Center - Hillcrest San Diego, California, United States
  • Smilow Cancer Center/Yale-New Haven Hospital New Haven, Connecticut, United States
View all 16 locations
View Trial Details
Active, Not Recruiting

Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone Metastasis

NCT03317392

Conditions
Castration-Resistant Prostate Carcinoma, Genital Diseases, Genital Diseases, Male, +10 more
Locations
  • UC San Diego Moores Cancer Center La Jolla, California, United States
  • University of California Davis Comprehensive Cancer Center Sacramento, California, United States
  • Smilow Cancer Center/Yale-New Haven Hospital New Haven, Connecticut, United States
  • Yale University New Haven, Connecticut, United States
View all 22 locations
View Trial Details

Related conditions